KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Net Income towards Common Stockholders: 2010-2024

Historic Net Income towards Common Stockholders for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to $131,000.

  • TherapeuticsMD's Net Income towards Common Stockholders rose 342.86% to $102,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $229,000, marking a year-over-year decrease of 64.82%. This contributed to the annual value of $131,000 for FY2024, which is 105.08% up from last year.
  • According to the latest figures from FY2024, TherapeuticsMD's Net Income towards Common Stockholders is $131,000, which was up 105.08% from -$2.6 million recorded in FY2023.
  • TherapeuticsMD's 5-year Net Income towards Common Stockholders high stood at $110.9 million for FY2022, and its period low was -$183.5 million during FY2020.
  • Its 3-year average for Net Income towards Common Stockholders is $36.2 million, with a median of $131,000 in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 219.13% in 2022, then plummeted by 102.33% in 2023.
  • TherapeuticsMD's Net Income towards Common Stockholders (Yearly) stood at -$183.5 million in 2020, then soared by 49.27% to -$93.1 million in 2021, then skyrocketed by 219.13% to $110.9 million in 2022, then crashed by 102.33% to -$2.6 million in 2023, then soared by 105.08% to $131,000 in 2024.